Jens Hachenberg1, Christian Eichler2,3,4, Ellen Acis2, Maximilian Mattes Auer-Schmidt5, Mathias Warm2,3, Wolfram Malter2,5, Fabinshy Thangarajah2. 1. Department of Gynecology and Obstetrics, Hannover Medical School, Hannover, Germany; Hachenberg.Jens@mh-hannover.de. 2. Department of Gynecology and Obstetrics, University of Cologne, Cologne, Germany. 3. Department of Gynecology and Obstetrics, Frauenklinik Holweide, Kliniken der Stadt Köln, Cologne, Germany. 4. German Center for Material Science in Gynecology and Senology (DZMGS), Cologne, Germany. 5. Faculty of Medicine and University Hospital Cologne, The University of Cologne, Cologne, Germany.
Abstract
BACKGROUND/AIM: Postoperative infection in implant-based reconstructive breast surgery is a common problem. The preoperative application of a disinfecting washing agent may reduce postoperative infection rates. This retrospective analysis aimed to evaluate whether preoperative Octenisan® application yields a reduction in postoperative complications or infection rates in breast reconstructive surgery. PATIENTS AND METHODS: Between 2016 and 2019, 127 women received implant-based breast reconstruction at the municipal hospital of Cologne, Holweide, Germany. A total of 197 treatments were performed. After giving consent, patients were asked to use Octenisan® wash lotion for five days before breast reconstructive surgery. All patients were asked by a simple questionnaire whether they performed showering and washing according to the proposed protocol. In 96 cases patients did adhere to the protocol. In 101 cases they did not. Patient cohorts were then divided into patients who had applied Octenisan® wash lotion and patients who had not. Endpoints were defined as minor complications with no implant loss and major complications with consecutive implant loss. RESULTS: Patient adherence to the application regimen was 48.7%. Overall minor complications occurred in 34.4% with preoperative Octenidine usage and 36.6% without preoperative Octenidine usage. Major complications happened in 7% with preoperative Octenidine and 5% without Octenidine. Overall, there was no significant difference concerning minor or major complication rates. CONCLUSION: Preoperative washing protocols involving the Octenisan® wash lotion is relatively cheap and easy to follow. There is evidence that washing protocols result in a reduction of S. aureus infections leading to a better perioperative outcome. Octenisan® is safe to use in implant-based breast reconstructive surgery and is not associated with higher risks for patients. Our study did not yield any significant reduction in perioperative and postoperative complication and infection rates. This is attributed to a relatively low study population. Wash lotion compliance was only 48.7%. Proper patient education is crucial. With those preliminary data, it is now possible to design a larger analysis since patient adherence to washing protocol with Octenisan® wash lotion has been established. Copyright
BACKGROUND/AIM: Postoperative infection in implant-based reconstructive breast surgery is a common problem. The preoperative application of a disinfecting washing agent may reduce postoperative infection rates. This retrospective analysis aimed to evaluate whether preoperative Octenisan® application yields a reduction in postoperative complications or infection rates in breast reconstructive surgery. PATIENTS AND METHODS: Between 2016 and 2019, 127 women received implant-based breast reconstruction at the municipal hospital of Cologne, Holweide, Germany. A total of 197 treatments were performed. After giving consent, patients were asked to use Octenisan® wash lotion for five days before breast reconstructive surgery. All patients were asked by a simple questionnaire whether they performed showering and washing according to the proposed protocol. In 96 cases patients did adhere to the protocol. In 101 cases they did not. Patient cohorts were then divided into patients who had applied Octenisan® wash lotion and patients who had not. Endpoints were defined as minor complications with no implant loss and major complications with consecutive implant loss. RESULTS:Patient adherence to the application regimen was 48.7%. Overall minor complications occurred in 34.4% with preoperative Octenidine usage and 36.6% without preoperative Octenidine usage. Major complications happened in 7% with preoperative Octenidine and 5% without Octenidine. Overall, there was no significant difference concerning minor or major complication rates. CONCLUSION: Preoperative washing protocols involving the Octenisan® wash lotion is relatively cheap and easy to follow. There is evidence that washing protocols result in a reduction of S. aureus infections leading to a better perioperative outcome. Octenisan® is safe to use in implant-based breast reconstructive surgery and is not associated with higher risks for patients. Our study did not yield any significant reduction in perioperative and postoperative complication and infection rates. This is attributed to a relatively low study population. Wash lotion compliance was only 48.7%. Proper patient education is crucial. With those preliminary data, it is now possible to design a larger analysis since patient adherence to washing protocol with Octenisan® wash lotion has been established. Copyright
Authors: Amy C Degnim; Alyssa D Throckmorton; Sarah Y Boostrom; Judy C Boughey; Andrea Holifield; Larry M Baddour; Tanya L Hoskin Journal: Ann Surg Oncol Date: 2012-06-26 Impact factor: 5.344
Authors: Benedetta Allegranzi; Peter Bischoff; Stijn de Jonge; N Zeynep Kubilay; Bassim Zayed; Stacey M Gomes; Mohamed Abbas; Jasper J Atema; Sarah Gans; Miranda van Rijen; Marja A Boermeester; Matthias Egger; Jan Kluytmans; Didier Pittet; Joseph S Solomkin Journal: Lancet Infect Dis Date: 2016-11-02 Impact factor: 25.071
Authors: Heidi S M Ammerlaan; Jan A J W Kluytmans; Hanneke Berkhout; Anton Buiting; Els I G B de Brauwer; Peterhans J van den Broek; Paula van Gelderen; Sander A C A P Leenders; Alewijn Ott; Clemens Richter; Lodewijk Spanjaard; Ingrid J B Spijkerman; Frank H van Tiel; G Paul Voorn; Mireille W H Wulf; Jan van Zeijl; Annet Troelstra; Marc J M Bonten Journal: J Antimicrob Chemother Date: 2011-06-30 Impact factor: 5.790
Authors: Lonneke G M Bode; Jan A J W Kluytmans; Heiman F L Wertheim; Diana Bogaers; Christina M J E Vandenbroucke-Grauls; Robert Roosendaal; Annet Troelstra; Adrienne T A Box; Andreas Voss; Ingeborg van der Tweel; Alex van Belkum; Henri A Verbrugh; Margreet C Vos Journal: N Engl J Med Date: 2010-01-07 Impact factor: 91.245
Authors: P Gastmeier; M Behnke; A-C Breier; B Piening; F Schwab; M Dettenkofer; C Geffers Journal: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz Date: 2012-11 Impact factor: 1.513